Cargando…

Expression of Potential Targets for Cell-Based Therapies on Melanoma Cells

Tumor antigen-specific redirection of cytotoxic T cells (CTLs) or natural killer (NK) cells including chimeric antigen receptor (CAR-) and T cell receptor (TCR-) cell therapy is currently being evaluated in different tumor entities including melanoma. Expression of melanoma-specific antigen recogniz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strobel, Sophia B., Machiraju, Devayani, Hülsmeyer, Ingrid, Becker, Jürgen C., Paschen, Annette, Jäger, Dirk, Wels, Winfried S., Bachmann, Michael, Hassel, Jessica C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064084/ https://www.ncbi.nlm.nih.gov/pubmed/33805080 http://dx.doi.org/10.3390/life11040269

Ejemplares similares

TCR-Directed Therapy in the Treatment of Metastatic Uveal Melanoma
por: Strobel, Sophia B., et al.
Publicado: (2022)

Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients
por: Machiraju, Devayani, et al.
Publicado: (2021)

Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma
por: Machiraju, Devayani, et al.
Publicado: (2021)

Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment
por: Strobel, Sophia B., et al.
Publicado: (2021)

Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients
por: Machiraju, Devayani, et al.
Publicado: (2023)

Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA)
por: Hassel, Jessica C., et al.
Publicado: (2022)

Rapid disease progression on immune checkpoint inhibitors in young patients with stage IV melanoma
por: Machiraju, Devayani, et al.
Publicado: (2023)

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
por: Mitwasi, Nicola, et al.
Publicado: (2020)

Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells
por: Schilling, Bastian, et al.
Publicado: (2013)

Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022)

Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptors
por: Immisch, Lena, et al.
Publicado: (2023)

Computationally-Guided Development of a Stromal Inflammation Histologic Biomarker in Lung Squamous Cell Carcinoma
por: Xia, Daniel, et al.
Publicado: (2018)

Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptors
por: Kropp, Korbinian N., et al.
Publicado: (2023)

EGFR-Targeted Granzyme B Expressed in NK Cells Enhances Natural Cytotoxicity and Mediates Specific Killing of Tumor Cells
por: Oberoi, Pranav, et al.
Publicado: (2013)

Arming NK cells with enhanced antitumor activity: CARs and beyond
por: Oberoi, Pranav, et al.
Publicado: (2013)

Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma
por: Hassel, Jessica C.
Publicado: (2021)

Innate-like NKp30(+)CD8(+) T cells armed with TCR/CAR target tumor heterogeneity
por: Correia, Margareta P., et al.
Publicado: (2021)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

Immunotherapies for the Treatment of Uveal Melanoma—History and Future
por: Schank, Timo E., et al.
Publicado: (2019)

Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial
por: Grabbe, Pia, et al.
Publicado: (2021)

Assessment of early metabolic progression in melanoma patients under immunotherapy: an (18)F-FDG PET/CT study
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe)
por: Hassel, Jessica C., et al.
Publicado: (2017)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model
por: Schrörs, Barbara, et al.
Publicado: (2017)

S100 as Serum Tumor Marker in Advanced Uveal Melanoma
por: Salzmann, Martin, et al.
Publicado: (2023)

Quantitative Dynamic (18)F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma
por: Ritter, Cathrin, et al.
Publicado: (2017)

Human innate immune cell crosstalk induces melanoma cell senescence
por: Funck, Felix, et al.
Publicado: (2020)

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
por: Zhang, Congcong, et al.
Publicado: (2017)

Application of the long axial field-of-view PET/CT with low-dose [(18)F]FDG in melanoma
por: Sachpekidis, Christos, et al.
Publicado: (2022)

Innate RIG-I signaling restores antigen presentation in tumors and overcomes T cell resistance
por: Thier, Beatrice, et al.
Publicado: (2021)

The prognostic value of [(18)F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria
por: Sachpekidis, Christos, et al.
Publicado: (2023)

Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
por: Buder-Bakhaya, Kristina, et al.
Publicado: (2018)

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
por: Eitler, Jiri, et al.
Publicado: (2021)

Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotype
por: Albrecht, Lea Jessica, et al.
Publicado: (2022)

Which melanoma patient carries a BRAF-mutation? A comparison of predictive models
por: Eigentler, Thomas, et al.
Publicado: (2016)

Anti‐PD‐1 antibodies in metastatic uveal melanoma: a treatment option?
por: Bender, Carolin, et al.
Publicado: (2017)

Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers
por: Pfeifer Serrahima, Jordi, et al.
Publicado: (2023)

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
por: Burger, Michael C., et al.
Publicado: (2019)

Phenotype, function and T cell receptor repertoire of tumor-infiltrating lymphocytes in patients with pancreatic ductal adenocarcinoma
por: Poschke, Isabel, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g4ti27u5t0cj56moifoce8jvdq